Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies

A. Yap, M. A. Lopez-Olivo, J. Dubowitz, G. Pratt, J. Hiller, V. Gottumukkala, E. Sloan, B. Riedel, R. Schier

Research output: Contribution to journalReview ArticleResearchpeer-review

25 Citations (Scopus)

Abstract

Background: The biological perturbation associated with psychological and surgical stress is implicated in cancer recurrence. Preclinical evidence suggests that beta-blockers can be protective against cancer progression. We undertook a meta-analysis of epidemiological and perioperative clinical studies to investigate the association between beta-blocker use and cancer recurrence (CR), disease-free survival (DFS), and overall survival (OS). 

Methods: Databases were searched until September 2017, reported hazard ratios (HRs) pooled, and 95% confidence intervals (CIs) calculated. Comparative studies examining the effect of beta-blockers (selective and non-selective) on cancer outcomes were included. The Newcastle Ottawa Scale was used to assess methodological quality and bias. 

Results: Of the 27 included studies, nine evaluated the incidental use of non-selective beta-blockers, and ten were perioperative studies. Beta-blocker use had no effect on CR. Within subgroups of cancer, melanoma was associated with improved DFS (HR 0.03, 95% CI 0.01–0.17) and OS (HR 0.04, 95% CI 0.00–0.38), while endometrial cancer had an associated reduction in DFS (HR 1.40, 95% CI 1.10–1.80) and OS (HR 1.50, 95% CI 1.12–2.00). There was also reduced OS seen with head and neck and prostate cancer. Non-selective beta-blocker use was associated with improved DFS and OS in ovarian cancer, improved DFS in melanoma, but reduced OS in lung cancer. Perioperative studies showed similar variable effects across cancer types, albeit from a limited data pool. 

Conclusion: Beta-blocker use had no evident effect on CR. The beneficial effect of beta-blockers on DFS and OS in the epidemiological or perioperative setting remains variable, tumour-specific, and of low-level evidence at present.

Original languageEnglish
Pages (from-to)45-57
Number of pages13
JournalBritish Journal of Anaesthesia
Volume121
Issue number1
DOIs
Publication statusPublished - 1 Jul 2018

Keywords

  • beta-blockers
  • cancer recurrence
  • disease-free survival
  • overall survival
  • perioperative

Cite this